Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Skye Bioscience Inc
(NQ:
SKYE
)
4.260
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Skye Bioscience Inc
MarketBeat Week in Review – 10/7 - 10/11
October 12, 2024
Stocks delivered another winning week, but the latest inflation readings dampened hopes for aggressive rate cuts and turned attention toward earnings
Via
MarketBeat
Topics
Artificial Intelligence
Economy
Exposures
Artificial Intelligence
Economy
Interest Rates
Don’t Sleep on Skye Bioscience—This Weight Loss Drug Could Soar
October 09, 2024
Skye Bioscience has incredible potential upside, according to Wall Street analysts. It is striving to make a new weight loss drug, that could work with GLP-1s.
Via
MarketBeat
3 High-Risk, High-Reward Micro-Cap Stocks You Shouldn't Ignore
October 04, 2024
Check out these three micro-cap companies that have a big opportunity to succeed, but also significant a risk of failure.
Via
MarketBeat
Topics
Bankruptcy
Exposures
Financial
Legal
Skye Bioscience, Inc. (SKYE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
August 16, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Skye Bioscience, Inc. (SKYE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
August 08, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
SKYE Investors Have Opportunity to Join Skye Bioscience, Inc. Fraud Investigation with the Schall Law Firm
August 04, 2024
From
The Schall Law Firm
Via
Business Wire
Beacon Biosignals Announces Strategic Collaboration with Skye Bioscience to Integrate Sleep Quality and Sleep Apnea Endpoints in CBEYOND™ Phase 2 Trial of Nimacimab for Obesity
July 24, 2024
From
Beacon Biosignals
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.